Teleflex Incorporated (TFX) Stock Price & Analysis
Teleflex Incorporated (TFX) closed at USD 136.58 on Thursday, October 22, 2026, up 4.74% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 130.4; the Oct 22, 2026 session ranged USD 131.49–137.02 on volume of 697,968 shares. Market capitalization is $5.79B, with a 52-week range of USD 100.18–145 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 09:25 UTC.
Also available as compact Markdown for AI agents: nexqual.com/TFX.md
Key facts (TFX)
- Last four reported quarters (through Jun 30, 2026): revenue $2.25B, net income -$1.03B (-45.8% margin), free cash flow $168M (SEC filings).
- 3 of 80 tracked superinvestors hold TFX (13F, Q2 2026): 0 new, 0 added, 3 reduced, 0 unchanged.
- Analysts: Buy (mean 2.17 on a 1–5 scale) (12 analysts), mean target USD 154 (range 138–170).
- Total return with dividends: 1Y +4.3% vs S&P 500 +14.9%; 5Y -62.3% vs S&P 500 +80.3%.
- Next earnings: 2026-11-05, EPS estimate USD 1.89, revenue estimate $565M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (TFX)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $2.81B | $2.79B | $1.71B | $1.70B | $1.99B | $2.25B |
| Gross profit | $1.55B | $1.53B | $1.04B | $1.04B | $1.12B | — |
| Operating income | $628M | $500M | $259M | $104M | $118M | $44.4M |
| Net income | $485M | $363M | $356M | $69.7M | -$906M | -$1.03B |
| EPS (diluted) | $10.23 | $7.68 | $7.53 | $1.48 | -$20.25 | — |
| Free cash flow | $581M | $264M | $160M | $211M | $1.4M | $168M |
| Gross margin | 55.2% | 54.9% | 60.7% | 61.0% | 56.2% | — |
| Operating margin | 22.4% | 17.9% | 15.1% | 6.1% | 5.9% | 2.0% |
| Net margin | 17.3% | 13.0% | 20.8% | 4.1% | -45.4% | -45.8% |
| Revenue growth | +10.7% | -0.7% | -38.6% | -0.8% | +17.2% | — |
| Cash + short-term investments | $445M | $292M | $223M | $248M | $379M | — |
| Total debt | $1.85B | $1.71B | $1.82B | $1.66B | $2.64B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (TFX)
P/S 2.6x · EV/EBITDA 43.0x · EV/Sales 3.7x · P/FCF 34.4x · P/B 2.0x · FCF yield 2.91% · Earnings yield -17.83% · Dividend yield (paid, TTM) 1.03% · Buyback yield (TTM) 4.32% · Net debt $2.51B · EV $8.30B
P/E at fiscal year-ends: Dec 2024 120.3x, Dec 2023 33.1x.
Superinvestors (SEC 13F-HR, Q2 2026) (TFX)
3 of 80 tracked investors hold TFX. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Abrams Bison Investments, LLC | 4.91% | $101M | Reduced -20.7% | |
| Seth Klarman | Baupost Group | 3.30% | $179M | Reduced -11.7% |
| Richard Pzena | Pzena Investment Management | 0.22% | $76.5M | Reduced -13.7% |
Analysts (TFX)
Consensus Buy (mean 2.17 on a 1–5 scale), 12 analysts; mean target USD 154 (low 138, high 170).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-14 | Truist Securities | Target lowered | Hold | $150 → $142 |
| 2026-09-28 | B of A Securities | Upgrade | Neutral → Buy | $145 → $158 |
| 2026-08-25 | Needham | Target raised | Buy | $159 → $170 |
| 2026-08-11 | UBS | Target raised | Neutral | $145 → $158 |
| 2026-08-10 | Truist Securities | Target raised | Hold | $143 → $150 |
| 2026-08-07 | Piper Sandler | Target raised | Overweight | $160 → $169 |
| 2026-07-31 | Needham | Target raised | Buy | $147 → $159 |
| 2026-07-28 | UBS | Initiated | Neutral | $145 |
| 2026-07-15 | Mizuho | Target raised | Neutral | $140 → $145 |
| 2026-07-09 | BMO Capital | Initiated | Outperform | $159 |
Total return (dividends reinvested) (TFX)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +4.3% | -62.3% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +4.4% | -17.7% |
| Volatility (annualized) | 40.0% | 34.5% |
| Max drawdown | -24.1% (Oct 2025→Jan 2026) | -71.8% (Oct 2021→Jan 2026) |
TFX analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $1.89 | $1.82 | +3.7% | $565.4M | 11 |
| Next quarter (ends Dec 2026) | $2.12 | $2.23 | -4.8% | $584.0M | 11 |
| Current fiscal year (ends Dec 2026) | $7.08 | $6.70 | +5.7% | $2.27B | 10 |
| Next fiscal year (ends Dec 2027) | $10.94 | $10.58 | +3.4% | $2.37B | 12 |
Key Statistics (as of October 23, 2026 at 09:25 UTC)
| Price | USD 136.58 |
|---|---|
| Change | ▲ 4.74% (up) |
| Previous Close | USD 130.4 |
| Open | USD 132.3 |
| Day Range | USD 131.49 – 137.02 |
| 52-Week Range | USD 100.18 – 145 |
| Volume | 697,968 shares |
| Market Cap | $5.79B |
| Exchange | NYQ |
Technical Analysis (TFX)
Nexqual's technical model rates TFX "BUY" based on 5 bullish and 2 bearish signals across 127 daily candles, as of October 23, 2026 at 09:25 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 63.56 (neutral) |
| vs SMA50 | Above (USD 130.9) |
| MACD | 0.72 (positive) |
Analyst Ratings (TFX)
Wall Street analysts rate TFX "Buy" based on 12 analysts, with a mean price target of USD 154 (range USD 138–170), per Nexqual as of October 23, 2026 at 09:25 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 12 |
| Mean Target | USD 154 |
| High Target | USD 170 |
| Low Target | USD 138 |
| Buy / Hold / Sell | 6 / 6 / 0 |
Earnings (TFX)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD 1.89 |
| Revenue Estimate | $565.36M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 1.76 vs est 1.28 ▲ beat |
| 2026-03-31 | USD 1.39 vs est 1.21 ▲ beat |
| 2025-12-31 | USD 1.93 vs est 3.75 ▼ miss |
| 2025-09-30 | USD 3.67 vs est 3.38 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:25 UTC.
Financials & Fundamentals (TFX)
| Total Revenue | $2.25B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +28.90% |
| Gross Margin | +55.11% |
| Operating Margin | +10.06% |
| Profit Margin | -45.76% |
| ROE | -0.70% |
| Debt / Equity | 1.01 |
| Current Ratio | 2.6 |
| Total Cash | $323.94M |
| Total Debt | $2.94B |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $168.40M (7.5% of revenue) |
Source: Nexqual, October 23, 2026 at 09:25 UTC.
Financial Health Score (TFX)
Nexqual rates Teleflex Incorporated's overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 09:25 UTC.
| Growth | Critical — Revenue -35% YoY (annual), sharp decline |
|---|---|
| Profitability | Strong — Gross margin 55%, operating 10% (last 12 months) |
| Balance Sheet | Mixed — $300M cash and investments vs $2.81B debt (Jun 2026, SEC) |
| Cash Flow | Solid — FCF $168M (last 4 quarters to Jun 2026, SEC), 7% margin |
| Efficiency | Critical — ROE -1%, ROA 1.7% |
Ownership (TFX)
| Insider Ownership | +0.63% |
|---|---|
| Institutional Ownership | +114.91% |
| Shares Outstanding | 42.37M |
| Float | 42.21M |
| Short % of Float | +15.00% |
Source: Nexqual, October 23, 2026 at 09:25 UTC.
Leadership (TFX)
Teleflex Incorporated is led by Jason Weidman, President, CEO & Director, per Nexqual as of October 23, 2026 at 09:25 UTC.
| President, CEO & Director | Jason Weidman |
|---|---|
| Executive VP & CFO | John R. Deren |
| Corporate Vice President of Human Resources & Communications | Cameron P. Hicks |
| Vice President of Investor Relations & Strategy Development | Lawrence Soren Keusch |
| Vice President of Corporate Development | Matt Tomkin |
Major Backers & Investors (TFX)
Notable institutional backers of Teleflex Incorporated include Jupiter Topco LLC, T. Rowe Price, JANUS INVESTMENT FUND-Janus Henderson Enterprise Fund, according to Nexqual as of October 23, 2026 at 09:25 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Jupiter Topco LLC | 10.25% |
| T. Rowe Price | 7.54% |
| JANUS INVESTMENT FUND-Janus Henderson Enterprise Fund | 6.81% |
| Sessa Capital IM, L.P. | 3.6% |
| Millennium Management | 3.4% |
| BAUPOST GROUP LLC/MA | 3.33% |
| Fuller & Thaler Asset Management Inc. | 3.12% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 12.82% |
| Vanguard Group | 10.41% |
| State Street | 3.5% |
Source: Nexqual, October 23, 2026 at 09:25 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MMSI | Merit Medical Systems, Inc. | USD 93.94 | ▲ 2.78% |
| STVN | Stevanato Group S.p.A. | USD 19.5 | ▲ 3.61% |
| MMED | MiniMed Group, Inc. | USD 18.29 | ▲ 2.75% |
| BLCO | Bausch + Lomb Corporation | USD 17.43 | ▲ 1.46% |
| ICUI | ICU Medical, Inc. | USD 168.33 | ▲ 4.66% |
| ATR | AptarGroup, Inc. | USD 128.1 | ▲ 1.97% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:25 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt